The addition of androgen deprivation therapy (ADT) to escalated external beam radiotherapy may improve biochemical failure-free survival in men with intermediate-risk prostate cancer. However, the addition of ADT does not appear to provide an overall survival (OS) benefit. John Schieszer has the latest on the story in today’s Medical Minute.

Continue Reading